Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more) AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Adaptive Biotechnologies Corporation ADPT

Healthcare Biotechnology
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ... see more

Current News (NDAQ:ADPT)

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire 13 days ago

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

GlobeNewswire January 27, 2026

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

GlobeNewswire January 22, 2026

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

GlobeNewswire January 12, 2026

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 30, 2025

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

GlobeNewswire December 15, 2025

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

GlobeNewswire December 9, 2025

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

GlobeNewswire December 6, 2025

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

GlobeNewswire November 24, 2025
View More News ››

Opinion & Analysis (NDAQ:ADPT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ADPT)

Be the first to post on this bullboard.

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral and diamond properties in ...
View More »

Podcasts